Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Assets Average: 2020-2025

Historic Assets Average for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $215.6 million.

  • Foghorn Therapeutics' Assets Average fell 32.30% to $215.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.6 million, marking a year-over-year decrease of 32.30%. This contributed to the annual value of $284.9 million for FY2024, which is 17.50% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Assets Average stood at $215.6 million for Q3 2025, which was down 11.08% from $242.5 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Assets Average ranged from a high of $504.0 million in Q1 2022 and a low of $197.3 million during Q3 2021.
  • For the 3-year period, Foghorn Therapeutics' Assets Average averaged around $298.0 million, with its median value being $296.2 million (2024).
  • As far as peak fluctuations go, Foghorn Therapeutics' Assets Average soared by 125.76% in 2022, and later crashed by 32.30% in 2025.
  • Over the past 5 years, Foghorn Therapeutics' Assets Average (Quarterly) stood at $352.9 million in 2021, then climbed by 18.84% to $419.4 million in 2022, then fell by 28.55% to $299.7 million in 2023, then declined by 1.17% to $296.2 million in 2024, then slumped by 32.30% to $215.6 million in 2025.
  • Its last three reported values are $215.6 million in Q3 2025, $242.5 million for Q2 2025, and $271.3 million during Q1 2025.